Jaguar Health, Inc. (JAGX) — SEC Filings

Latest SEC filings for Jaguar Health, Inc. (JAGX), explained in plain English.

Sentiment Overview: 2 bearish, 47 neutral, 1 mixed

Recent Filings (50)

• Jaguar Health Files 8-K on Financials — 8-K · 2026-04-07T08:35:22-04:00 [neutral] Risk: medium
  Jaguar Health, Inc. filed an 8-K on April 7, 2026, reporting on its results of operations and financial condition. The filing includes financial statements and
• Jaguar Health Files 2025 10-K Annual Report — 10-K · 2026-04-07T06:10:28-04:00 [neutral] Risk: medium
  Jaguar Health, Inc. filed its 10-K annual report on April 7, 2026, for the fiscal year ending December 31, 2025. The filing includes various exhibits such as th
• 8-K Filing — 8-K · 2025-12-12T00:00:00.000Z [neutral]
• Jaguar Health Files 8-K on Shareholder Votes & Financials — 8-K · 2025-12-08T00:00:00.000Z [neutral] Risk: low
  Jaguar Health, Inc. filed an 8-K on December 8, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial sta
• Jaguar Health Files 8-K: Agreements, Obligations, Equity Sales — 8-K · 2025-11-19T00:00:00.000Z [neutral] Risk: medium
  On November 17, 2025, Jaguar Health, Inc. entered into a material definitive agreement. The company also incurred a direct financial obligation or an obligation
• Jaguar Health Enters Material Definitive Agreement — 8-K · 2025-11-14T00:00:00.000Z [neutral] Risk: medium
  On November 14, 2025, Jaguar Health, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as J
• Jaguar Health Seeks Shareholder Nod for Key Equity Issuances — DEF 14A · 2025-11-10T00:00:00.000Z [mixed] Risk: high
  Jaguar Health, Inc. (JAGX) is convening a Special Meeting of Stockholders on December 8, 2025, to seek approval for two critical proposals under Nasdaq Listing
• Jaguar Health Files 8-K on Equity Sales — 8-K · 2025-10-03T00:00:00.000Z [neutral] Risk: medium
  On September 30, 2025, Jaguar Health, Inc. filed an 8-K report detailing unregistered sales of equity securities. The company, formerly known as Jaguar Animal H
• Jaguar Health Files 8-K: Material Agreement & Equity Sales — 8-K · 2025-10-01T00:00:00.000Z [neutral] Risk: medium
  On September 28, 2025, Jaguar Health, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
• Jaguar Health Files 8-K: Agreements, Equity Sales, Bylaw Changes — 8-K · 2025-09-11T00:00:00.000Z [neutral] Risk: medium
  On September 9, 2025, Jaguar Health, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement, unregis
• Jaguar Health Files 8-K: Corporate Updates — 8-K · 2025-08-19T00:00:00.000Z [neutral] Risk: low
  On August 19, 2025, Jaguar Health, Inc. filed an 8-K report detailing matters submitted to a vote of security holders, Regulation FD disclosures, and financial
• Jaguar Health Files 8-K on Material Agreement — 8-K · 2025-08-14T00:00:00.000Z [neutral] Risk: medium
  On August 14, 2025, Jaguar Health, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibit
• Jaguar Health's Losses Widen Amid Rising Expenses, Cash Dwindles — 10-Q · 2025-08-14T00:00:00.000Z [bearish] Risk: high
  Jaguar Health, Inc. reported a net loss of $10.56 million for the three months ended June 30, 2025, an increase from a net loss of $9.63 million in the same per
• Jaguar Health Files Proxy Materials — DEFA14A · 2025-08-06T00:00:00.000Z [neutral] Risk: low
  Jaguar Health, Inc. filed a Definitive Additional Materials (DEFA14A) on August 6, 2025. This filing is related to their proxy statement and indicates no fee wa
• Jaguar Health Details Executive Equity Awards, Compensation Structure — DEF 14A · 2025-07-21T00:00:00.000Z [neutral] Risk: medium
  Jaguar Health, Inc. (JAGX) filed its DEF 14A on July 21, 2025, outlining executive compensation and governance matters for the fiscal year ended December 31, 20
• Jaguar Health Files 8-K: Material Agreements and Equity Sales — 8-K · 2025-06-30T00:00:00.000Z [neutral] Risk: medium
  On June 27, 2025, Jaguar Health, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregis
• Jaguar Health Files 8-K: Agreements, Obligations, Equity Sales — 8-K · 2025-06-24T00:00:00.000Z [neutral] Risk: medium
  On June 24, 2025, Jaguar Health, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreement, cre
• Jaguar Health Files 8-K: Material Agreement, Equity Sales — 8-K · 2025-05-22T00:00:00.000Z [neutral] Risk: medium
  On May 20, 2025, Jaguar Health, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and prov
• Jaguar Health Reports Financial Obligations and Equity Sales — 8-K · 2025-05-15T00:00:00.000Z [neutral] Risk: medium
  On May 13, 2025, Jaguar Health, Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported on its
• Jaguar Health Files 10-Q, Details Financial Agreements — 10-Q · 2025-05-15T00:00:00.000Z [neutral] Risk: medium
  Jaguar Health, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details various financial instruments and agreements, including convertible
• Jaguar Health Files 8-K with Financials and Exhibits — 8-K · 2025-05-09T00:00:00.000Z [neutral] Risk: low
  On May 9, 2025, Jaguar Health, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD Disclosure.
• Jaguar Health Files 8-K: Material Agreement & Financials — 8-K · 2025-05-05T00:00:00.000Z [neutral] Risk: low
  On May 5, 2025, Jaguar Health, Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, formerly known as Jagua
• Jaguar Health Files 8-K on Equity Sales — 8-K · 2025-05-02T00:00:00.000Z [neutral] Risk: medium
  On April 30, 2025, Jaguar Health, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing also includes financial statements and
• Jaguar Health Files 8-K with Financials and Exhibits — 8-K · 2025-04-30T00:00:00.000Z [neutral] Risk: low
  On April 30, 2025, Jaguar Health, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regul
• Jaguar Health Files 8-K with Exhibits — 8-K · 2025-04-28T00:00:00.000Z [neutral] Risk: low
  On April 28, 2025, Jaguar Health, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosu
• Jaguar Health Files 8-K/A Amendment — 8-K/A · 2025-04-25T00:00:00.000Z [neutral] Risk: medium
  Jaguar Health, Inc. filed an 8-K/A on January 29, 2025, to amend a previous filing. The amendment pertains to the entry into a material definitive agreement, th
• 8-K Filing — 8-K · 2025-04-21T00:00:00.000Z [neutral]
• Jaguar Health Files 10-K/A Amendment — 10-K/A · 2025-04-15T00:00:00.000Z [neutral] Risk: low
  Jaguar Health, Inc. filed a 10-K/A amendment on April 15, 2025, for the fiscal year ending December 31, 2024. The filing includes data related to equity awards
• Jaguar Health Files 8-K: Regulatory, Other Events & Financials — 8-K · 2025-04-04T00:00:00.000Z [neutral] Risk: medium
  Jaguar Health, Inc. filed an 8-K on April 4, 2025, reporting events as of March 31, 2025. The filing includes information related to Regulation FD Disclosure, O
• Jaguar Health Files 2024 10-K, Details Financial Agreements — 10-K · 2025-03-31T00:00:00.000Z [neutral] Risk: medium
  Jaguar Health, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as Jaguar Animal Health, Inc., is involved in the p
• Jaguar Health Files 8-K: Agreements, Obligations, Equity Sales — 8-K · 2025-03-26T00:00:00.000Z [neutral] Risk: medium
  On March 26, 2025, Jaguar Health, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreement, cr
• Jaguar Health Files 8-K on Security Holder Rights — 8-K · 2025-03-18T00:00:00.000Z [neutral] Risk: medium
  On March 18, 2025, Jaguar Health, Inc. filed an 8-K report detailing material modifications to the rights of its security holders and amendments to its articles
• Jaguar Health Files 8-K: Shareholder Vote & Financials — 8-K · 2025-03-13T00:00:00.000Z [neutral] Risk: low
  On March 13, 2025, Jaguar Health, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders, a Regulation FD disclosure, and fina
• Jaguar Health Files 8-K on Key Corporate Changes — 8-K · 2025-02-27T00:00:00.000Z [neutral] Risk: medium
  On February 26, 2025, Jaguar Health, Inc. filed an 8-K report detailing several significant events. These include the entry into a material definitive agreement
• Jaguar Health Files Definitive Proxy Statement — DEF 14A · 2025-02-24T00:00:00.000Z [neutral] Risk: low
  Jaguar Health, Inc. filed a definitive proxy statement (DEF 14A) on February 24, 2025, for its annual meeting of stockholders. The filing concerns the solicitat
• Jaguar Health Files 8-K on New Agreement and Accountant Change — 8-K · 2025-02-20T00:00:00.000Z [neutral] Risk: medium
  Jaguar Health, Inc. filed an 8-K on February 20, 2025, reporting on two key events that occurred on February 19, 2025. The company entered into a Material Defin
• Jaguar Health Files 8-K on Definitive Agreement & Equity Sales — 8-K · 2025-02-04T00:00:00.000Z [neutral] Risk: medium
  On January 28, 2025, Jaguar Health, Inc. entered into a material definitive agreement related to the creation of a direct financial obligation. The company also
• Jaguar Health Q3 2024: Losses Continue Amidst Financing Deals — 10-Q · 2024-11-13T00:00:00.000Z [bearish] Risk: high
  Jaguar Health, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss for the nine months ended September 30, 2024, and h
• Jaguar Health Files 8-K on Financials — 8-K · 2024-08-13T00:00:00.000Z [neutral] Risk: low
  On August 13, 2024, Jaguar Health, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, along wi
• Jaguar Health Files Q2 2024 10-Q — 10-Q · 2024-08-13T00:00:00.000Z [neutral] Risk: medium
  Jaguar Health, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operatio
• Jaguar Health Files 8-K: Corporate Details Updated — 8-K · 2024-07-23T00:00:00.000Z [neutral] Risk: low
  On July 23, 2024, Jaguar Health, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The filing includes inform
• SC 13G/A Filing — SC 13G/A · 2024-07-22T00:00:00.000Z [neutral]
• Jaguar Health Enters Material Definitive Agreement — 8-K · 2024-07-18T00:00:00.000Z [neutral] Risk: medium
  On July 17, 2024, Jaguar Health, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this a
• Jaguar Health Raises $1.5M in Private Placement — 8-K · 2024-07-16T00:00:00.000Z [neutral] Risk: medium
  Jaguar Health, Inc. announced on July 15, 2024, the closing of a private placement of its common stock, raising approximately $1.5 million. The company also iss
• Jaguar Health CFO Resigns, Interim Appointed — 8-K · 2024-06-26T00:00:00.000Z [neutral] Risk: medium
  On June 25, 2024, Jaguar Health, Inc. filed an 8-K report detailing the resignation of its Chief Financial Officer, Arthur J. Sim. The company also announced th
• Jaguar Health Files 8-K on Shareholder Votes & Financials — 8-K · 2024-06-21T00:00:00.000Z [neutral] Risk: low
  Jaguar Health, Inc. filed an 8-K on June 21, 2024, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statem
• Jaguar Health Reports Unregistered Equity Sales — 8-K · 2024-06-10T00:00:00.000Z [neutral] Risk: medium
  Jaguar Health, Inc. filed an 8-K on June 10, 2024, reporting unregistered sales of equity securities. The filing details transactions that occurred on June 7, 2
• SC 13G/A Filing — SC 13G/A · 2024-06-10T00:00:00.000Z [neutral]
• Jaguar Health Files Definitive Proxy Statement — DEFA14A · 2024-05-31T00:00:00.000Z [neutral] Risk: low
  Jaguar Health, Inc. filed a Definitive Proxy Statement (DEFA14A) on May 31, 2024, related to its upcoming annual meeting. The filing indicates no fee was requir
• Jaguar Health Files 8-K: Stock, Bylaws, and Agreements Updated — 8-K · 2024-05-23T00:00:00.000Z [neutral] Risk: medium
  On May 17, 2024, Jaguar Health, Inc. entered into a Material Definitive Agreement related to its common stock. The company also made modifications to the rights